Valve-in-valve transcatheter aortic valve implantation overcoming hostile anatomy: Evolut R for the treatment of Mitroflow bioprosthesis dysfunction

Neil Ruparelia, Antonio Colombo, Azeem Latib

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Redo surgery is regarded as the first-line treatment option for patients presenting with prosthetic valve degeneration. However, many patients have concomitant co-morbidities and this option is associated with significant risk. Transcatheter valve-in-valve implantation is an alternative strategy depending on the bioprosthetic valve that is being treated. The Sorin Mitroflow bioprosthetic aortic valve has been regarded as a contraindication to valve-in-valve treatment due to the high risk of coronary obstruction. We here present the case of a patient with small peripheral vasculature who underwent successful transfemoral valve-in-valve implantation and subsequently discuss the challenges and technical aspects that require consideration.

Original languageEnglish
Pages (from-to)292-295
Number of pages4
JournalCardiovascular Intervention and Therapeutics
Volume31
Issue number4
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Bioprosthesis
Anatomy
Aortic Valve
Therapeutics
Morbidity
Transcatheter Aortic Valve Replacement

Keywords

  • Coronary obstruction
  • Evolut R
  • Mitroflow
  • Transcatheter aortic valve implantation
  • Valve-in-valve

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Valve-in-valve transcatheter aortic valve implantation overcoming hostile anatomy : Evolut R for the treatment of Mitroflow bioprosthesis dysfunction. / Ruparelia, Neil; Colombo, Antonio; Latib, Azeem.

In: Cardiovascular Intervention and Therapeutics, Vol. 31, No. 4, 01.10.2016, p. 292-295.

Research output: Contribution to journalArticle

@article{87527cf1a2354bc0993d976726988cf5,
title = "Valve-in-valve transcatheter aortic valve implantation overcoming hostile anatomy: Evolut R for the treatment of Mitroflow bioprosthesis dysfunction",
abstract = "Redo surgery is regarded as the first-line treatment option for patients presenting with prosthetic valve degeneration. However, many patients have concomitant co-morbidities and this option is associated with significant risk. Transcatheter valve-in-valve implantation is an alternative strategy depending on the bioprosthetic valve that is being treated. The Sorin Mitroflow bioprosthetic aortic valve has been regarded as a contraindication to valve-in-valve treatment due to the high risk of coronary obstruction. We here present the case of a patient with small peripheral vasculature who underwent successful transfemoral valve-in-valve implantation and subsequently discuss the challenges and technical aspects that require consideration.",
keywords = "Coronary obstruction, Evolut R, Mitroflow, Transcatheter aortic valve implantation, Valve-in-valve",
author = "Neil Ruparelia and Antonio Colombo and Azeem Latib",
year = "2016",
month = "10",
day = "1",
doi = "10.1007/s12928-015-0354-0",
language = "English",
volume = "31",
pages = "292--295",
journal = "Cardiovascular Intervention and Therapeutics",
issn = "1868-4300",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Valve-in-valve transcatheter aortic valve implantation overcoming hostile anatomy

T2 - Evolut R for the treatment of Mitroflow bioprosthesis dysfunction

AU - Ruparelia, Neil

AU - Colombo, Antonio

AU - Latib, Azeem

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Redo surgery is regarded as the first-line treatment option for patients presenting with prosthetic valve degeneration. However, many patients have concomitant co-morbidities and this option is associated with significant risk. Transcatheter valve-in-valve implantation is an alternative strategy depending on the bioprosthetic valve that is being treated. The Sorin Mitroflow bioprosthetic aortic valve has been regarded as a contraindication to valve-in-valve treatment due to the high risk of coronary obstruction. We here present the case of a patient with small peripheral vasculature who underwent successful transfemoral valve-in-valve implantation and subsequently discuss the challenges and technical aspects that require consideration.

AB - Redo surgery is regarded as the first-line treatment option for patients presenting with prosthetic valve degeneration. However, many patients have concomitant co-morbidities and this option is associated with significant risk. Transcatheter valve-in-valve implantation is an alternative strategy depending on the bioprosthetic valve that is being treated. The Sorin Mitroflow bioprosthetic aortic valve has been regarded as a contraindication to valve-in-valve treatment due to the high risk of coronary obstruction. We here present the case of a patient with small peripheral vasculature who underwent successful transfemoral valve-in-valve implantation and subsequently discuss the challenges and technical aspects that require consideration.

KW - Coronary obstruction

KW - Evolut R

KW - Mitroflow

KW - Transcatheter aortic valve implantation

KW - Valve-in-valve

UR - http://www.scopus.com/inward/record.url?scp=84988643034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988643034&partnerID=8YFLogxK

U2 - 10.1007/s12928-015-0354-0

DO - 10.1007/s12928-015-0354-0

M3 - Article

AN - SCOPUS:84988643034

VL - 31

SP - 292

EP - 295

JO - Cardiovascular Intervention and Therapeutics

JF - Cardiovascular Intervention and Therapeutics

SN - 1868-4300

IS - 4

ER -